Macrolide use in the treatment of critically ill patients with pneumonia: Incidence, correlates, timing and outcomes

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 24, Issue 4, 2013, Pages

  Sligl, Wendy I ^a   Hoang, Holly ^b   Eurich, Dean T ^c   Malhotra, Atul ^d   Marrie, Thomas J ^e   Majumdar, Sumit R ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Faculty of Medicine and Dentistry   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d HARVARD UNIVERSITY   (United States)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Critical care; Intensive care; Lung; Macrolides; Mortality; Pneumonia

Indexed keywords

MACROLIDE;

ADULT; ANTIBIOTIC THERAPY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; CRITICALLY ILL PATIENT; FEMALE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PNEUMONIA;

EID: 84892154200     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/652512     Document Type: Article

References (39)

1. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10 1999:1-203.
2. Ioachimescu OC, Ioachimescu AG, Iannini PB. Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: A 5-year experience. Int J Antimicrob Agents 2004; 24:485-90.
3. Lamy O, Van Melle G, Cornuz J, Burnand B. Clinical management of immunocompetent hospitalized patients with community-acquired pneumonia. Eur J Intern Med 2004; 15:28-34.
4. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: Use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002; 166:717-23.
5. Lee JH, Ryu YJ, Chun EM, Chang JH. Outcomes and prognostic factors for severe community-acquired pneumonia that requires mechanical ventilation. Korean J Intern Med 2007; 22:157-63.
6. Valencia M, Badia JR, Cavalcanti M, et al. Pneumonia severity index class V patients with community-acquired pneumonia: Characteristics, outcomes, and value of severity scores. Chest 2007; 132:515-22.
7. Bartlett JG, Breiman R F, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: Guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998; 26:811-38.
8. Mandell LA, Bartlett JG, Dowell S F, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-33.
9. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31:383-421.
10. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72.
11. Hoban DJ, Wierzbowski AK, Nichol K, Zhanel GG. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimicrob Agents Chemother 2001; 45:2147-50.
12. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm D F. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: Results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis 2003; 36:963-70.
13. Thornsberry C, Sahm D F, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: Results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002; 34(Suppl 1):S4-S16.
14. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005; 18:125-31.
15. Giamarellos-Bourboulis EJ. Immunomodulatory therapies for sepsis: Unexpected effects with macrolides. Int J Antimicrob Agents 2008; 32(Suppl 1):S39-43.
16. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689-98.
17. Schultz MJ. Macrolide activities beyond their antimicrobial effects: Macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54:21-8.
18. Baddour LM, Yu VL, Klugman K P, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440-4.
19. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36:612-20.
20. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33:153-9.
21. Rodriguez A, Mendia A, Sirvent JM, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35:1493-8.
22. Johnstone J, Eurich DT, Majumdar SR, Jin Y, Marrie TJ. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: A population-based cohort study. Medicine (Baltimore) 2008; 87:329-34.
23. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: Population based prospective cohort study. BMJ 2006; 333:999.
24. Sligl WI, Eurich DT, Marrie TJ, Majumdar SR. Only severely limited, premorbid functional status is associated with short- and long-term mortality in patients with pneumonia who are critically ill: A prospective observational study. Chest 2011; 139:88-94.
25. Sligl WI, Eurich DT, Marrie TJ, Majumdar SR. Age still matters: Prognosticating short- and long-term mortality for critically ill patients with pneumonia. Crit Care Med 2010; 38:2126-32.
26. Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: A prospective study of patients not initially admitted to the ICU. Chest 2005; 127:1260-70.
27. Marrie TJ, Shariatzadeh MR. Community-acquired pneumonia requiring admission to an intensive care unit: A descriptive study. Medicine (Baltimore) 2007; 86:103-11.
28. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164:637-44.
29. Westley B P, Chan PA. Questions remain regarding mandatory use of macrolides in community-acquired pneumonia. Intensive Care Med 2010; 36:1787; author reply 9-90.
30. Ortega M, Marco F, Soriano A, Gomez J, Almela M, Mensa J. In vitro antagonism between beta-lactam and macrolide in Streptococcus pneumoniae: How important is the antibiotic order? Int J Antimicrob Agents 2004; 24:178-80.
31. Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt-Moller N. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. J Antimicrob Chemother 2000; 46:973-80.
32. Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: A prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180:861-6.
33. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31:2742-51.
34. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237-48.
35. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-96.
36. Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: Increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202-9.
37. Cilloniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66:340-6.
38. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: Prevalence, pathogens, and presentation. Chest 2008; 134:1141-8.
39. Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Impact of guideline-concordant antibiotics and macrolide/beta-lactam combinations in 3203 patients hospitalized with pneumonia: Prospective cohort study. Clin Microbiol Infect 2013; 19:257-64.